Release Date: 2024-02-12

History of Gene Therapy

Diclehan Oral (Author)

Release Date: 2024-02-12

Gene therapy aims to treat genetic diseases by introducing genetic material into cells to correct medical conditions or enhance health. This involves using nucleic acids, viruses, or genetically modified microorganisms to integrate therapeutic genetic material into the recipient’s genome. Recent advancements have significantly progressed gene therapy, focusing on treating inherited and acquired diseases like cancer [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inGene Therapy
    First Page1
    Last Page16
    DOIhttps://doi.org/10.69860/nobel.9786053358824.1
    Page Count16
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Gene therapy aims to treat genetic diseases by introducing genetic material into cells to correct medical conditions or enhance health. This involves using nucleic acids, viruses, or genetically modified microorganisms to integrate therapeutic genetic material into the recipient’s genome. Recent advancements have significantly progressed gene therapy, focusing on treating inherited and acquired diseases like cancer and cardiovascular ailments through clinical trials. Overcoming delivery efficiency and immune reaction challenges is crucial for widespread clinical use. Gene therapy is categorized into germline and somatic gene transplantation, with somatic alterations not being passed to future generations. Rapid developments in molecular biology since the 1990s have expanded gene therapy’s potential to address genetic defects and various diseases, with promising results from animal experiments leading to human trials.

    Diclehan Oral (Author)
    Assistant Professor, Dicle University
    https://orcid.org/0000-0002-0074-0602
    3Dr. Diclehan Oral is a distinguished academic specializing with a Ph.D. in Medical Biology. She earned her bachelor’s degree in Biology from Dicle University in 1986 and completed her master’s degree in Medical Biology and Genetics at the Health Sciences Institute of Dicle University in 1998. Her dissertation focused on cytogenetic analysis and gene mutations in human diseases. Her master’s thesis focused on the effects of Bleomycin on chromosomal aberrations in smokers under the supervision of Assist. Prof. Dr. Nail Alp. Dr. Oral obtained her Ph.D. in Medical Biology and Genetics from the same university in 2004, with her doctoral research on genetic investigations in couples with recurrent spontaneous abortions, also supervised by Assist. Prof. Dr. Nail Alp. She began her academic career as a research assistant at the Faculty of Medicine, Dicle University, serving from 1989 to 2006. Since then, she has been a faculty member, holding the position of Assistant Professor.

    • Baltimore D. Viral RNA-dependent DNA polymerase: RNA-dependent DNA polymerase in virions of RNA tumour viruses. Nature 1970;226(5252):1209-11.

    • Jackson D, Symons R, Berg P. Biochemical method for inserting new genetic information into DNA of Simian Virus 40: Circular SV40 DNA molecules containing lambda phage genes and the galactose operon of Escherichia coli. Proc Natl Acad Sci USA 1972;69(10):2904-9.

    • Lobban P, Kaiser A. Enzymatic end-to end joining of DNA molecules. J Mol Biol 1973;78(3):453-71. 53 / 4, Volume 53 Issue 4, December 2014

    • Cohen S, Chang A, Boyer H, Helling R. Construction of biologically functional bacterial plasmids in vitro. Proc Natl Acad Sci USA 1973;70(11):3240-4.

    • Williamson B. Gene therapy. Nature 1982;298(5873):416-8.

    • Watson JD. Gene therapy: How ripe the time? Lancet 1981;317(8213):196-7.

    • Wolff JA, Lederberg J. An early history of gene transfer and therapy. Hum Gene Ther 1994;5(4):469-80.

    • Wade N. Gene therapy caught in more entanglements. Science 1981;212(4490): 21-4.

    • Griffith, F., 1928. The Significance of Pneumococcal Types. J. Hyg. (Lond) 27, 113– 159.

    • Guo, J., Xin, H., 2006. Chinese gene therapy. Splicing out the West? Science 314, 1232–1235.

    • Sanlioglu A, Karacay B, Benson P, Engelhardt J, et al., Novel approaches to augment adeno-associated virus type-2 endocytosis and transduction. Virus Res, 2004. 104(1): p. 51-9.

    • Sanlioglu AD, Griffith TS, Omer A, Dirice E, et al., Molecular mechanisms of death ligand-mediated immune modulation: a gene therapy model to prolong islet survival in type 1 diabetes. J Cell Biochem, 2008. 104(3): p. 710-20

    • Sanlioglu S, Benson P, Engelhardt JF, Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology, 2000. 268(1): p. 68-78.

    • Sanlioglu S, Benson PK, Yang J, Atkinson EM, et al., Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol- 3 kinase activation. J Virol, 2000. 74(19): p. 9184-96

    • Friedmann T, Medical ethics. Principles for human gene therapy studies. Science, 2000. 287(5461): p. 2163-5.

    • Edelstein ML, Abedi MR, Wixon J, Gene therapy clinical trials worldwide to 2007-- an update. J Gene Med, 2007. 9(10): p. 833-42.

    • Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, et al., Gene therapy for immunodeficiency due to adenosine deaminase deficiency.N Engl J Med, 2009. 360(5): p. 447-58.

    • Wirth T, Parker N, Yla-Herttuala S, History of gene therapy. Gene, 2013. 525(2): p. 162-9.

    • Xin H, Chinese gene therapy. Gendicine’s efficacy: hard to translate. Science, 2006. 314(5803): p. 1233.

    • Gene Therapy Clinical Trials Worldwide Database. The Journal of Gene Medicine. Wiley. June 2016. Archived from the original on 31 July 2020.

    • 21. Pearson S, Jia H, Kandachi K (January 2004). China approves first gene therapy. Nature Biotechnology. 22 (1): 3–4. doi:10.1038/nbt0104-3. PMC 7097065. PMID 14704685.

    • Gene Therapy for PAD Approved. 6 December 2011. Retrieved 5 August 2015.

    • Gallagher J (2 November 2012). Gene therapy: Glybera approved by European Commission. BBC News. Retrieved 15 December 2012.

    • Richards S (6 November 2012). Gene Therapy Arrives in Europe. The Scientist.

    • Beali A (25 January 2014). Gene therapy restores sight in people with eye disease. The New Scientist. Retrieved 25 January 2014.

    • Ghosh P (28 April 2016). Gene therapy reverses sight loss and is long-lasting. BBC News Online. Retrieved 29 April 2016.

    • Genetically Altered Skin Saves A Boy Dying Of A Rare Disease. NPR.org.

    • Summary of opinion1 (initial authorisation) Strimvelis. European Medicines Agency. 1 April 2016. pp. 1–2. Archived from the original on 28 January 2018. Retrieved 13 April 2016.

    • Hirscheler B (1 April 2016). Europe gives green light to first gene therapy for children. Reuters. Retrieved 13 April 2016.

    • Reeves R (6 June 2016). Second gene therapy wins approval in Europe. Bionews. Archived from the original on 21 February 2017. Retrieved 20 February 2017.

    • Coghlan A (9 April 2016). Gene Therapy Approved. New Scientist. No. 3068. pp. 8–9.

    • Whipple T (1 March 2017). New gene therapy ‘shrinks tumours like ice cubes. The Times. Retrieved 1 March 2017.

    • Coghlan A (March 2017). Gene therapy ‘cures’ boy of blood disease that affects millions. New Scientist.

    • FDA approves novel gene therapy to treat patients with a rare form of inherited vision loss. U.S. Food and Drug Administration (FDA) (Press release). 19 December 2017. Retrieved 20 December 2017

    • Zynteglo EPAR. European Medicines Agency (EMA). 25 March 2019. Retrieved 8 June 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

    • Single Ascending Dose Study in Participants With LCA10. clinicaltrials.gov. Retrieved 20 August 2019.

    • Allergan and Editas Medicine Initiate the Brilliance Phase 1/2 Clinical Trial of AGN- 151587 (EDIT-101) for the Treatment of LCA10. Editas Medicine. Retrieved 20 August 2019.

    • Marchione M (11 May 2021). AIDS virus used in gene therapy to fix ‘bubble baby’ disease. Stat. Retrieved 19 July 2021.

    • Gene therapy restores immune function in children with rare immunodeficiency. National Institutes of Health (NIH). 11 May 2021. Retrieved 19 July 2021.

    • Why Gene Therapy Caused Leukemia In Some ‘Boy In The Bubble Syndrome’ Patients. ScienceDaily. Retrieved 19 July 2021.

    • HIV used to cure ‘bubble boy’ disease. BBC News. 17 April 2019. Retrieved 19 July 2021.

    • Pittman J, Ravitz JD. These Scientists May Have Found a Cure for ‘Bubble Boy’ Disease. Smithsonian Magazine. Retrieved 19 July 2021.

    • Rohr K (17 April 2019). Gene therapy restores immunity in infants with rare immunodeficiency disease. National Institutes of Health (NIH). Retrieved 4 June 2020

    • Sena-Esteves M (14 February 2022). First gene therapy for Tay-Sachs disease successfully given to two children. The Conversation. Retrieved 7 March 2022.

    • Parents spark breakthrough gene therapy for children with Tay-Sachs disease. The Independent. 18 February 2022. Retrieved 7 March 2022.

    • Upstaza: Pending EC decision. European Medicines Agency. 19 May 2022. Archived from the original on 25 May 2022. Retrieved 22 May 2022. PTC Therapeutics Receives Positive CHMP Opinion for Upstaza for the Treatment of AADC Deficiency. PTC Therapeutics (Press release). 20 May 2022. Retrieved 22 May 2022

    • Commissioner, Office of the (19 May 2023). FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa. FDA. Retrieved 31 July 2023

    • Gene therapy eyedrops restored a boy’s sight. Similar treatments could help millions. AP News. 24 July 2023. Retrieved 31 July 2023

    • Commissioner, Office of the (23 June 2023). FDA Approves First Gene Therapy for Treatment of Certain Patients with Duchenne Muscular Dystrophy. FDA. Retrieved 12 July 2023.

    • HUGO Ethics Committee (April 2001). Statement on Gene Therapy Research (PDF). Human Genome Organization. Archived from the original (PDF) on 7 September 2008

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!